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Abstract. Prior antibiotic use, contamination, limited blood volume, and processing delays reduce yield of blood cul-
tures for detection of Streptococcus pneumoniae. We performed immunochromatographic testing (ICT) on broth from
incubated blood culture bottles and real-time lytA polymerase chain reaction (PCR) on broth and whole blood and com-
pared findings to blood culture in patients with suspected bacteremia. We selected 383 patients in Mali and 586 patients
in Thailand based on their blood culture results: 75 and 31 were positive for pneumococcus, 100 and 162 were positive
for other pathogens, and 208 and 403 were blood culture negative, respectively. ICT and PCR of blood culture broth
were at least 87% sensitive and 97% specific compared with blood culture; whole blood PCR was 75–88% sensitive and
96–100% specific. Pneumococcal yields in children < 5 years of age increased from 2.9% to 10.7% in Mali with > 99% of
additional cases detected by whole blood PCR, and from 0.07% to 5.1% in Thailand with two-thirds of additional cases
identified by ICT. Compared with blood culture, ICT and lytA PCR on cultured broth were highly sensitive and specific
but their ability to improve pneumococcal identification varied by site. Further studies of these tools are needed before
widespread implementation.
INTRODUCTION
Pneumonia is a leading cause of child morbidity and mor-
tality worldwide.1,2 Clinical trials of pneumococcal conjugate
vaccines (PCV) have shown that Streptococcus pneumoniae is
responsible for 20–37% of chest X-ray positive pneumonia in
children < 5 years of age.3–5 Etiological diagnosis of bacterial
pneumonia relies primarily on blood culture that yields a posi-
tive result in 5–10% of hospitalized patients; a subset of these
are identified as pneumococcus.6–8 Several factors reduce the
sensitivity of blood culture, including small blood volumes, anti-
biotic pretreatment, specimen contamination by other organisms
because of poor specimen collection or processing technique,
prolonged transport time, and inconsistent availability of sup-
plies. These factors are particularly common in resource-poor
settings.9–11 However, even under optimal conditions, blood
cultures identify only 30% of suspected cases of pneumococcal
pneumonia,5,12 limiting the ability of surveillance to accurately
estimate disease burden and evaluate the impact of vaccines.
The Binax NOW® antigen assay (Alere, Waltham, MA) for
S. pneumoniae is a rapid immunochromatographic test (ICT)
licensed for testing of urine from adult pneumonia patients
and of cerebrospinal fluid (CSF) from meningitis patients of
all ages.13 In children, the Binax ICT has limited value for
testing urine, as it cannot distinguish pneumococcal pneumo-
nia from nasopharyngeal (NP) colonization.14–19 In contrast,
the test is 90–100% sensitive and specific when testing CSF
from meningitis patients of all ages compared with culture,
latex agglutination, and polymerase chain reaction (PCR). ICT
also enables detection of a large number of pneumococcal
meningitis cases among patients with negative CSF results.20–23
Recent data suggest that ICT may also be used to identify
pneumococcus from blood specimens that indicate bacterial
growth after incubation in automated culture systems but fail
to yield an organism on subculture.24–26
Molecular methods such as PCR may further enhance
pneumococcal detection in patients with suspected invasive
pneumococcal disease (IPD).27–31 Moreover, multiplex con-
ventional and real-time PCR can be used to identify serotype-
specific capsular genes in clinical specimens,32,33 providing
valuable data on the serotype distribution of culture-negative
specimens.34,35 However, it is uncertain whether a positive
real-time lytA PCR result from blood can be triggered by col-
onization alone36,37 (PERCH presentation ISPPD 2014).
National policies regarding the use of PCVs are based, in
part, on disease burden estimates. The challenge of obtaining
these data from low- and middle-income countries where the
burden of pneumococcal disease is thought to be very high
further emphasizes the urgency of better diagnostics. The
objective of the Laboratory Evaluation of Assays for Pneumo-
coccus (LEAP) study was to assess the performance of the
Binax NOW ICT on blood culture broth and of real-time PCR
for lytA on whole blood and blood culture broth for the diag-
nosis of pneumococcal bacteremia in Thailand and Mali.
METHODS
Patient enrollment and specimen collection. This study
was nested in existing IPD surveillance projects in Mali and
Thailand (Table 1). In Mali, all inpatients 0–15 years and
outpatients 0–35 months of age presenting to Hôpital Gabriel
Touré, the main pediatric referral hospital in Bamako, with
fever ≥ 39°C or a suspicion of meningitis, pneumonia, or sep-
sis and providing informed consent were eligible for inclusion
in this study. Study participants had blood collected and inoc-
ulated into a blood culture bottle for immediate processing at
the hospital microbiology laboratory. Blood collected concur-
rently with blood cultures was also processed, and serum and
whole blood were stored frozen at −80°C until further testing.
In Thailand, blood cultures were collected as clinically indi-
cated from hospitalized patients of all ages identified at the
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18 district hospitals and two provincial hospitals in Sa Kaeo
and Nakhon Phanom provinces and processed at the provin-
cial hospital laboratory as part of routine surveillance. Cultures
collected at district hospitals were maintained at 15–30°C and
transported within 24 hours to the provincial hospitals for pro-
cessing. Patients who consented to participate in a related
study on respiratory pathogens also provided whole blood and
NP swabs, but these were usually obtained at a different time
than blood culture specimens, often after initiation of antimi-
crobial treatment. Whole blood and NP specimens collected at
district hospitals were transported to the provincial hospitals
where they were frozen at −70°C before shipping on dry ice to
Bangkok for testing. Whole blood specimens were stored on
ice packs for a median of 26 hours (interquartile range [IQR]:
19–36 hours) before freezing. At both sites, a filter paper disc
was saturated with 20 μL of patient serum and frozen before
testing for the presence of antimicrobial activity.
Laboratory methods. All blood cultures were processed
using automated culture systems: the BACTEC 9060 system
(Beckton-Dickinson, Sparks, MD) was used in Mali and the
BacT/ALERT 3D system (bioMerieux, Hazelwood, MI) was
used in Thailand. Cultures with a positive signal in the auto-
mated system (i.e., alarm-positive cultures) were subcultured
by standard methods.
Aliquots of blood culture broth from included patients
were frozen between −80°C and −70°C for batch testing by
ICT and PCR. Serum was tested for the presence of anti-
microbial agents by assessing its ability to inhibit growth of a
pan-sensitive Staphylococcus aureus ATCC 25923 strain, as
described previously.11
ICT was performed on blood culture specimens after
thawing to room temperature according to the manufacturer’s
instructions for testing urine and CSF. The presence of a
control line was required to confirm test validity. In Mali,
specimens were categorized as positive or negative based on
the presence or absence of a test line. In Thailand, previous
studies had shown that ICT results can sometimes be equivo-
cal,25 so we developed a scoring system a priori according to
the intensity of the color of the test line. Specimens with a
“very strong” or “strong” test line were considered positive
while those with a “weak” or absent test line were considered
negative. A single technician was responsible for conduct-
ing the tests at each site, averting any inter-rater variability
in interpretation.
Technicians from both sites were trained to conduct real-
time lytA PCR and sequential multiplex serotyping PCR on
blood culture broth and whole blood specimens at the Centers
for Disease Control and Prevention Streptococcus Labora-
tory in Atlanta, GA, using the first 25% of study specimens
and then completed all remaining testing in-country. Real-
time PCR for pneumococcus (lytA gene) detection was
performed as previously described for all specimens included
in this study.28 In brief, 200 μL of whole blood ethylene-
diaminetetraacetic acid (EDTA) or 50 μL of blood cultured
broth was added to 100 μL of Tris-EDTA buffer containing
0.04 g/mL lysozyme and 75 U/mL mutanolysin (Sigma
Chemical Co., St. Louis, MO), and the mixture was incu-
bated for 1 hour at 37°C. DNA extraction was performed by
following Qiagen DNA Mini Kit instructions (Qiagen, Venlo,




Hospitals Two provincial hospitals and 18 district
hospitals in Sa Kaeo and Nakhon
Phanom provinces
Hôpital Gabriel Touré, the largest pediatric
hospital in Bamako, the capital city
Inclusion criteria note: specimens
from only a subset of these patients
were selected, as determined by the
blood culture results
Persons of all ages hospitalized with
suspicion of pneumonia and with a
blood culture obtained
Children < 16 years of age hospitalized with fever
(≥ 39°C) and/or suspicion of invasive bacterial
infection and with a blood culture obtained
Children < 5 years of age hospitalized
with suspicion of sepsis and with a blood
culture obtained
Children < 36 months of age treated as outpatient
with fever (≥ 39°C) and/or suspicion of
invasive bacterial infection and with a blood
culture obtained
Note: blood cultures obtained at
clinician discretion
Exclusion criteria None Newborns who have not yet been discharged
from the hospital
Informed consent Informed consent waiver granted Required
Subset of patients enrolled in a separate
pneumonia etiology study (RPS) consented
to sharing information with this study
Blood volume (target) Culture: 4 mL for < 5-year-olds, 10 mL for
all other ages
Culture: 1 mL for < 1 month, 2 mL for 1 month
to 4 years, 3 mL for > 4-year-olds
Whole blood: 2 mL for PCR (0.2 mL per
single PCR run; RPS subjects only)
Whole blood: 2 mL for PCR (0.2 mL per single
PCR run)
Serum: 0.5 mL for antimicrobial activity testing Serum: 0.5 mL for antimicrobial activity testing
NP swabs Yes for RPS patients No
Specimen transport procedures Blood culture bottle placed in automated
blood culture machine and blood transported
to laboratory within 4 hours for
serum separation
Blood culture bottle placed in automated blood
culture machine and serum transported to
laboratory within 1 hour
Blood for PCR and NP specimens collected after
blood for cultures, stored on ice until frozen at
−70°C at provincial hospital and then shipped
on dry ice to Bangkok for testing
Blood for PCR and serum collected simultaneously
with blood for culture, frozen at −80°C within
24 hours of collection
LEAP = laboratory evaluation of assays for Pneumococcus; NP = nasopharyngeal; PCR = polymerase chain reaction; RPS = respiratory pathogen study.
268 MOÏSI AND OTHERS
was diluted to 1:100 to1:1,000 to avoid PCR inhibition often
observed from specimens with extremely high pneumococcal
DNA concentrations. A whole blood EDTA sample was con-
sidered positive if its cycle threshold (Ct) value was ≤ 35 and
negative if its Ct value was > 40. If a Ct value was > 35 and
≤ 40, the specimen was diluted 10-fold and retested to deter-
mine whether PCR inhibitors were present. The specimen
was considered positive if the Ct value of the diluted specimen
was ≤ 35, equivocal if the Ct value was 36–40, and negative if
> 40. Multiplex real-time PCR for pneumococcal serotyping
was performed for lytA-positive whole blood and NP speci-
mens,38,39 whereas conventional multiplex PCR was used
to serotype lytA-positive incubated blood cultured broth.33 A
subset of specimens from both sites was sent to Atlanta for
quality control testing.
Selection of specimens for testing and analysis. Patients
were selected for inclusion into the LEAP study based on their
automated blood culture and subculture results, according to
four groups:
• Group 1: Blood culture positive for S. pneumoniae (posi-
tive controls).
• Group 2: Blood culture positive for another pathogen
(negative controls); this included patients culture positive
for any Streptococcus species other than S. pneumoniae
and for non-Streptococcus pathogens.
• Group 3: Alarm positive after incubation in an automated
blood culture system, subculture negative.
• Group 4: Alarm negative.
Statistical methods. Before enrollment began, sample sizes
sufficient to achieve the study objectives were estimated using
simulation. On the basis of the assumed conditional probabil-
ities relating the tests to each other, latent class analysis
(LCA) was used to determine adequate sample sizes. The
simulation and LCA were conducted in SAS Version 9.3 (SAS
Institute Inc., Cary, NC). The resultant target sample sizes for
Mali were 75 for group 1, 100 for group 2, 20 for group 3, and
200 for group 4. The corresponding targets for Thailand were
35, 100, 100, and 200, respectively. In Mali, if the total number
of specimens available for any given group exceeded the target,
we used random sampling to achieve the target number. In
Thailand, sampling was only done for group 4.
Data analysis. We estimated the sensitivity and specificity
of the ICT and lytA real-time PCR based on results from
culture-positive patients (groups 1 and 2) and the potential
additional pneumococcal yield achieved by testing culture-
negative cases (groups 3 and 4), stratified by study site, age,
clinical syndrome, antibiotic pretreatment, and NP pneumo-
coccal carriage status when available. Finally, for children
< 5 years of age, we calculated the increased pneumococcal
yield that could be achieved by adding each of the new diag-
nostics to blood culture as follows:
Increased pneumococcal yield¼Npositive by at least one test
Npositive by culture only
 1
To estimate the overall potential added yield of ICT and
PCR in these surveillance settings, we assumed that the pro-
portion positive among all blood culture–negative patients
was equal to the proportion observed in the sample of blood
culture–negative patients who were tested in this study.
Analyses were conducted in Stata 12 (Stata Corp., Col-
lege Station, TX) and Microsoft Excel (Microsoft Corp.,
Redmond, WA).
Ethical considerations. This study was conducted in accor-
dance with the ethical principles for human subjects research
of the Declaration of Helsinki and received approval from the
Institutional Review Boards of the Johns Hopkins Bloomberg
School of Public Health, University of Maryland School of
Medicine, Centers for Disease Control and Prevention, and
University of Bamako Faculty of Medicine, Pharmacy and
Dentistry and from the Ethical Committee for Human Sub-
jects Research of the Thailand Ministry of Public Health.
RESULTS
From a total of 5,086 patient blood cultures obtained in
Mali between January 25, 2010 and January 24, 2011, we
selected 383 (7.5% of total, 90.9% < 5 years of age) for inclu-
sion based on their blood culture findings: 75 positive controls
(group 1), 100 negative controls (group 2), 10 alarm-positive,
subculture-negative cases (group 3), and 198 alarm-negative
cases (group 4). In Thailand, 596 (4.1%) of 14,429 blood cul-
tures collected during May 2010 to April 2011 were included,
of which 39.4% were from patients < 5 years of age: 31 posi-
tive controls (group 1), 162 negative controls (group 2),
183 alarm-positive, subculture-negative cases (group 3), and
220 alarm-negative cases (group 4). We were unable to achieve
our target numbers of alarm-positive, subculture-negative
patients in Mali and culture-confirmed pneumococcal cases in
Thailand because of limited numbers of patients in each of
these groups. Patient characteristics are detailed in Table 2.
In Mali, most participants were young children and nearly
half had meningitis, in contrast with Thailand where a major-
ity were adults with pneumonia. At both sites, patients with
positive cultures were less likely to have had antibiotics
before culture collection (P = 0.03). In Mali, patients with
pneumococcal bacteremia were younger than the other three
inclusion groups (P < 0.01). In Thailand, pneumococcal car-
riage among those tested was found in 88% of eight positive
controls (all ≥ 5 years of age), 42% of 213 alarm-negative
patients (all < 5 years of age), and approximately 12% of the
other two groups (44 and 16 tested for groups 2 and 3, of
which 3 and 2 were < 5 years of age) (P < 0.01).
Table 3 shows ICT findings by site and study group. In Mali,
ICT sensitivity and specificity compared with blood culture
were both 100% (one-sided 95% confidence interval [CI]:
95.2–100% and 96.4–100%, respectively). In Thailand, sensi-
tivity and specificity among all ages were 87.1% (95% CI:
70.1–96.3%) and 96.9% (95% CI: 92.9–99.0%), respectively
(Table 3); among children < 5 years of age, sensitivity (based
on only two cases of pneumococcal bacteremia) and specificity
(based on nine cases of non-pneumococcal bacteremia) were
50% (95% CI: 1.3–98.7%) and 89% (95% CI: 51.7–99.7%),
respectively. All five negative controls in Thailand with a positive
ICT result had a Streptococcus species other than S. pneumoniae
identified by culture (three alpha-hemolytic viridans-like strepto-
cocci and two Group A streptococci, of which one also had
Shigella flexneri detected). Of note, an additional 115 non-
pneumococcal streptococci had a negative ICT result in Thailand;
the negative control group in Mali did not include any patients
that were culture positive for non-pneumococcal streptococci.
In Mali, ICT was negative for all 208 patients that were blood
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culture negative (groups 3 and 4). In Thailand, 10 of 403
(2.5%) blood culture–negative cases were ICT positive, mostly
among the alarm-negative subgroup (group 4): nine of 220
(4.1%) compared with one of 183 (0.55%) alarm-positive,
subculture-negative (group 3) cases. Of the 10, eight were from
children < 5 years of age, four had an admission diagnosis of
pneumonia and six of an other syndrome, and two had docu-
mented pneumococcal NP colonization (among eight tested);
none had serum antibiotic results available.
Real-time PCR on blood culture broth compared with cul-
ture was 100% (one-sided 95% CI: 96.4–100%) sensitive
and 98.9% (95% CI: 93.6–100%) specific in Mali and 90.3%
(95% CI: 74.2–98.0%) sensitive and 100% (one-sided 95%
CI: 97.7–100%) specific in Thailand (Table 4). PCR on cul-
tured broth did not yield any additional positives among
blood culture–negative patients at either site. Quality control
of PCR on blood culture broth produced identical results to
initial testing for both sites (29 positive and four negative
specimens tested in Mali, 10 positive and 33 negative speci-
mens tested in Thailand).
Whole blood was available for PCR testing from 381 (99%)
patients in Mali and 228 (38%) in Thailand (Table 5). In
Mali, real-time PCR on whole blood was 87.8% (95% CI:
78.2–94.3%) sensitive and 96.0% (95% CI: 90.0–98.9%) spe-
cific (positive in one each of Haemophilus influenzae type b,
Klebsiella pneumoniae, S. aureus, and group D Salmonella).
On quality control testing, eight of 13 positive controls and
one of two negative controls that had originally tested posi-
tive were found negative by real-time PCR. Because thawing
of specimens during transport may have degraded DNA, we
used only the original testing results in the final analysis. In
Thailand, real-time PCR on whole blood was 37.5% (95%
CI: 8.5–75.5%) sensitive (based on the eight culture-confirmed
pneumococcal cases with blood specimens available) and
100% (one-sided 95% CI: 91.4–100%) specific from initial
testing, with sensitivity increasing to 75.0% (95% CI: 34.9–
96.8%) after quality control testing (three new positives
identified) and specificity reduced (one positive of two nega-
tive controls tested). Fifteen patients were positive and three
equivocal by whole blood PCR among 207 culture-negative
patients in Mali (8.7% yield) compared with only three posi-
tives among 179 tested in Thailand (1.7% yield); a fourth
positive was detected during quality control testing of 42 culture-
negative, whole blood PCR–negative specimens in Thailand,
increasing the yield to 2.2%. In the culture-negative group,
quality control testing found nine negatives among 12 PCR-
positive specimens in Mali and one negative of two PCR pos-
itives in Thailand. Again, because of the possibility of DNA
degradation during transport, these quality control results
were not considered in the final analysis.
We estimated the potential increase in pneumococcal yield
that could be achieved in children < 5 years of age if all
patients who had a blood culture were tested by ICT and
real-time PCR according to our protocol, based on the sam-
pling fraction that was applied when selecting specimens for
each group (Figure 1). In Mali, pneumococcal yield increased
from 2.9% by culture alone to 10.3% with the addition of lytA
real-time PCR on whole blood; the other two tests did not
improve yield further. In Thailand, yield by culture alone was
0.1%, increasing to 3.4% with the addition of the ICT and
5.6% with whole blood PCR. Because ICT and whole blood
PCR contributed differently to yield in the two sites, there
TABLE 2
Patient characteristics by study site
Characteristic
Thailand (N = 596) Mali (N = 383)
Group 1 (N = 31) Group 2 (N = 162) Group 3 (N = 183) Group 4 (N = 220) Group 1 (N = 75) Group 2 (N = 100) Group 3 (N = 10) Group 4 (N = 198)
n % n % n % n % n % n % n % n %
Age (years) P = 0.39* P < 0.01
< 1 1 3.2 5 3.1 7 3.8 69 31.4 42 56.0 41 41.0 5 50.0 104 52.5
1–4 1 3.2 4 2.5 0 0.0 144 65.5 26 34.7 44 44.0 0 0.0 86 43.4
5–14 2 6.5 3 1.9 8 4.4 0 0.0 7 9.3 15 15.0 5 50.0 8 4.0
15–64 16 51.6 89 54.9 108 59.0 5 2.3 – – – – – – – –
65 + 11 35.5 61 37.7 60 32.8 2 0.9 – – – – – – – –
Sex P = 0.48 P = 0.67
Male 21 67.7 98 60.5 100 54.7 129 58.6 42 56.0 55 55.0 5 50.0 121 61.1
Diagnosis† P < 0.01 P = 0.09
Meningitis 1 3.2 9 5.6 1 0.6 18 8.2 38 50.7 37 37.0 5 50.0 89 45.0
Pneumonia w/
pleural effusion
0 0.0 2 1.2 2 1.1 1 0.5 2 2.7 3 3.0 1 10.0 0 0.0
Pneumonia w/o
pleural effusion
15 48.4 23 14.2 36 19.7 153 69.6 20 26.7 23 23.0 2 20.0 59 29.8
Sepsis 6 19.4 69 42.6 47 25.7 20 9.1 0 0.0 2 2.0 0 0.0 2 1.0
Other 9 29.0 59 36.4 97 53.0 28 12.7 15 20.0 35 35.0 2 20.0 48 24.2
Prior antibiotics‡ P = 0.03 P = 0.03
Yes 0 0.0 8 8.8 24 20.0 9 13.0 6 8.0 15 15.0 2 20.0 45 22.7
No 19 100.0 83 91.2 96 80.0 60 87.0 69 92.0 85 85.0 8 80.0 153 77.3
NP carriage P < 0.01
Yes 7 87.5 5 11.4 2 12.5 90 42.3 – – – – – – – –
No 1 12.5 39 88.6 14 87.5 123 57.8 – – – – – – – –
Group 1: culture positive for Streptococcus pneumoniae; Group 2: culture positive for other pathogen; Group 3: alarm positive, subculture negative; Group 4: alarm negative. P values calculated
for comparison among groups within each site.
*P value comparing age distribution in groups 1–3, excluding group 4 cases that were selected among children < 5 years of age (except for seven patient enrollment errors).
†Clinician’s diagnosis at time of enrollment; “other” patients in Thailand had a range of syndromes including febrile illness without a focus, urinary tract infections, upper respiratory infections,
acute exacerbation of chronic obstructive pulmonary disease, heart disease, injury, and so on; “other” patients in Mali had febrile illness without a focus (72 outpatients) or other suspected invasive
disease (osteomyelitis, septic arthritis, endocarditis, etc.).
‡Prior antibiotic use based on serum disc antimicrobial activity test result.
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was insufficient crossover to successfully estimate sensitivity
and specificity using latent class analysis.
Serotyping by multiplex conventional or real-time PCR
yielded a serotype in 73 of 76 blood culture broth and 50 of
86 whole blood specimens that were positive or equivocal for
lytA in Mali, and in 28 of 28 broth and eight of 10 whole
blood specimens in Thailand. In Mali, results were concordant
for 46 of 65 patients with serotyping attempted on both speci-
mens (the remainder had one typable and one non-typable
specimen; none yielded two different known serotypes) com-
pared with four of six patients in Thailand (the other two
were 19A from broth/non-typable from whole blood and 19A
from broth/6 from whole blood). None of the four negative
controls from Mali with a positive whole blood PCR result
had a serotype identified from whole blood (one not tested,
three non-typable).
DISCUSSION
In this study, we aimed to assess the performance and poten-
tial contribution of the S. pneumoniae ICT and real-time PCR
for identification of cases of pneumococcal bacteremia. We
implemented the project in sites in Mali and Thailand along-
side ongoing surveillance projects that obtained blood for cul-
ture from well-characterized populations, and selected patients
based on their blood culture results to constitute a positive
control group, a negative control group, and a target group for
assessing increased detection of pneumococcal bacteremia. In
Mali, the ICT and real-time PCR were highly sensitive and
specific compared with blood culture, and real-time PCR on
whole blood identified possible pneumococcal cases among
culture-negative patients, producing a > 3-fold increase in yield
compared with culture alone in children < 5 years of age, from
2.9% to 10.3%. In Thailand, all three tests showed good sensi-
tivity and specificity, and both the ICT and the real-time PCR
on whole blood detected possible pneumococcal cases in the
culture-negative group, increasing the overall yield in children
< 5 years from < 0.1% to 5.6%.
The differences in findings between Mali and Thailand are
challenging to interpret. Patient populations differed greatly
between sites in terms of age, clinical syndrome, and hospitali-
zation status. Prior antibiotic use was similar based on serum
disc test results, but half of all patients in Thailand had no
specimen available for testing, leading to potential selection
bias. Blood cultures were collected systematically for all patients
meeting specific inclusion criteria in Mali, but only at clini-
cians’ discretion in Thailand. Whole blood was collected con-
currently with blood cultures in Mali. Conversely, in Thailand
whole blood was available only for patients enrolled in a sepa-
rate study and was often collected up to 24 hours after blood
culture; antibiotic exposure before whole blood collection was
therefore very likely even if it had not occurred before culture,
potentially affecting sensitivity of PCR on whole blood and
limiting additional case detection. Blood was immediately
transported to the on-site laboratory and processed or frozen
for later testing in Mali, whereas several hours of transport
time were required from the sites of specimen collection to the
laboratory in Thailand (for whole blood, median time from
collection to freezing: 26 hours, IQR: 19–36 hours). Different
automated blood culture machines and broth bottles were
used, possibly affecting ICT results: in another study in Thailand,


















































































































































































































































































































































































272 MOÏSI AND OTHERS
BacTAlert bottles but not on BACTEC aerobic bottles, point-
ing to potential cross-reactivity with the BacTAlert system.25
Longer specimen transport times in Thailand and different
blood culture systems may have contributed to the higher
numbers of alarm-positive cultures that were subculture neg-
ative compared with Mali. Different age distributions may
also have been a factor, as a higher percentage of specimens
from patients aged 5–14 years in both sites were alarm posi-
tive, subculture negative. Finally, in Thailand, many patients
who should have had a whole blood specimen available for
testing did not: this limited the sample size available for the
whole blood PCR analysis and potentially caused selection
bias. It is therefore likely that the tests improved ascertainment
of pneumococcal disease differently across sites because of dif-
ferences in patient populations and methodology. It is possible
that if we had sufficient sample size to compare results across
similar strata (in particular age, clinical syndrome, and prior
antibiotic use), we would obtain similar results in terms of sen-
sitivity, specificity and additional pneumococcal yield.
The ICT on blood culture broth performed well in both
sites in terms of sensitivity and specificity compared with cul-
ture, with false positives seen in Thailand in three patients with
blood cultures positive for a Streptococcus species known to
cross-react with the ICT and in two patients with group A
Streptococcal bacteremia.13 Additional possible pneumococcal
cases identified by ICT were substantial in Thailand and con-
centrated in children < 5 years. Only one of these additional
cases was detected among the alarm-positive, subculture-
negative group, which was unexpected and does not support
the hypothesis that alarm-positive subculture-negative cultures
result from pneumococcal infections that fail to grow on sub-
culture, as suggested in previous work from Thailand.25 ICT
detected no additional cases in Mali. Our findings are similar
to those from a study evaluating the ICT in CSF, in which the
ICT performed significantly better than culture and latex
agglutination in two Asian sites but similar to these assays in
three African sites.23 Too few patients in Thailand had serum
antibiotic data available to determine whether pretreatment
affected the relative yields of ICT and culture. There was
no difference in ICT yields among culture-negative patients
by NP carriage status, suggesting that cases identified only by
ICT likely represent true cases rather than false positives caused
by colonizing isolates or antigens entering the bloodstream.
Real-time lytA PCR on blood cultured broth was highly
sensitive and specific relative to blood culture, did not detect
any pneumococci among culture-negative patients, and was
consistent in field and quality control testing. In particular,
none of the culture-negative, ICT-positive cases were positive
by PCR on blood cultured broth; if these cases are truly pneu-
mococcal, this may point to a technical issue with broth PCR.
On whole blood, real-time PCR specificity was high in both
sites and sensitivity ranged from 75% in Thailand to nearly
90% in Mali. The number of specimens tested in Thailand
was low, and maximum sensitivity was only achieved by con-
sidering positive results from the local laboratory and those
from subsequent quality control testing overseen by a senior
laboratory scientist. It appears that many factors can affect
whole blood PCR results, including antibiotic pretreatment,
processing delays, testing delays, extraction methods, repeated
freeze-thaw cycles, and technician skill, with regular training
and quality control in an expert laboratory necessary to
achieve optimal results. Despite these limitations, whole blood
PCR produced a substantial increase in pneumococcal yield
over culture alone in children < 5 years of age in both sites
(but a smaller increase over culture and ICT combined in
Thailand). The absolute increase in yield from whole blood
PCR was of the same order of magnitude for the two sites
(+2.2% to +7.4%), and the final pneumococcal prevalence
accounting for ICT and PCR positives was 5.6% in Thailand
and 10.2% in Mali. Several observations suggest that many
culture-negative, whole blood PCR–positive cases may be true
pneumococcal cases. The great majority of them were chil-
dren < 5 years of age (16 of 18 in Mali and three of three in
Thailand) who were more likely to have false-negative blood
cultures because of low blood volumes. They appeared more
likely to have pre-culture antibiotic treatment than the general
FIGURE 1. Additional pneumococcal yield with immunochromatographic testing of blood culture broth and lytA polymerase chain reaction
(PCR) of whole blood.
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surveillance population (five of 18 or 28% in Mali versus 17%
among all subjects, one of one tested in Thailand), which may
have inhibited pneumococcal growth on culture. On the other
hand, all had negative ICT results on culture broth and few
were alarm positive (one in Mali, none in Thailand), which
runs counter to the hypothesis that cultured pneumococci
underwent autolysis prior to subculture. Given their age, they
were also more likely to be pneumococcal carriers, and there-
fore more likely to have a false-positive lytA PCR result.
Finally, our lack of a healthy control group limits our ability
to attribute disease in these patients to pneumococcus. The
detection of lytA in patients with blood cultures positive for
other pathogens supports that false-positive PCR results can
occur, suggesting that PCR-positive whole blood may be seen
in the absence of pneumococcal disease.
CONCLUSION
Clinical trials of pneumococcal conjugate vaccines have dem-
onstrated the poor sensitivity of blood culture for diagnosing
pneumococcal pneumonia,5,12 and numerous studies suggest
that its sensitivity may be lower in Asia than in Africa
because of widespread pre-culture antibiotic use. The use of
novel tools such as the ICT or real-time PCR on blood speci-
mens may increase case detection, help improve disease burden
estimates, and facilitate evaluations of PCV impact. Our study
has shown that the amount of benefit from these additional
assays may vary across settings; the decision to use either of
these tools should be made with careful consideration of spe-
cific objectives and of population characteristics.
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